Sign in
Taking peoplePhase 2

Adebrelimab, apatinib and etoposide for HER2-negative breast cancer that spread to the brain

Tests adebrelimab, apatinib and etoposide in adults with HER2-negative breast cancer brain metastasis.

Key facts

Who runs it
Beijing 302 Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis
Status
Recruiting
Phase
Phase 2
People taking part
30 people, planned
Started
10 Oct 2024
Expected to end
31 Dec 2026
Type of study
Interventional
Treatments tested
  • Adebrelimab
  • Apatinib
  • Etoposide
Record updated
10 December 2024

Who can take part

The trial is looking for women with HER2-negative breast cancer that has spread to the brain. The brain spread is new or has grown after treatment.

Age
18 years and older
Sex
Women only
Disease stage
Locally recurrent or metastatic HER2-negative breast cancer with new or growing brain metastasis. At least one brain tumor that can be measured (RECIST V1.1). Daily activity level ECOG PS 0-2. Expected survival of at least 3 months.
Earlier treatment
For HR+ cancer: a CDK4/6 inhibitor must have stopped working, or the doctor judges it cannot be used. Earlier whole-brain radiation, stereotactic radiosurgery or brain surgery is allowed. People treated before with Apatinib, Avelumab or VP-16 cannot join.
Biomarker or test result
HER2-negative, confirmed by tissue or cell test (IHC 0 or 1+; or IHC 2+ with negative ISH).
Main reasons for not taking part
  • Brain metastasis that needs urgent local treatment
  • HER2-positive cancer (IHC 3 or IHC 2 with ISH amplification)
  • Another cancer within 5 years, with some skin, cervical and thyroid cancer exceptions
  • Immune deficiency such as HIV, HCV, active hepatitis B, or a past organ transplant
  • Heart disease, severe organ problems, pregnancy or breastfeeding
Show the full registry criteria (21)Hide the full registry criteria

Who can take part

  • Female, aged ≥18 years
  • Expected survival time ≥3 months
  • Histologically or cytologically confirmed HER2-negative (IHC 0 or 1+; or IHC 2+ ISH negative) locally recurrent or metastatic disease
  • New brain metastasis or brain metastasis progression after treatment
  • HR+ advanced breast cancer with prior CDK4/6 inhibitor treatment failure or the investigator deems unsuitable for CDK4/6 inhibitors
  • At least one intracranial measurable lesion as defined by RECIST V1.1 criteria;
  • ECOG PS 0-2;
  • Patients must have the ability to swallow oral medication;
  • Prior WBRT, stereotactic radiosurgery, and surgical resection are allowed;
  • Organ function levels are basically normal, and the investigator believes that the study drug can be applied:
  • Voluntarily join this study, sign the informed consent, have good compliance, and are willing to cooperate with follow-up

Who cannot take part

  • Previously treated with Apatinib, Avelumab, or VP-16;
  • Inability to swallow, chronic diarrhea, and intestinal obstruction, with multiple factors affecting drug administration and absorption;
  • Severe dysfunction of important organs such as the heart, liver, or kidneys;
  • Participants diagnosed with any other malignant tumor within 5 years before this study, excluding non-melanoma skin cancer that has undergone radical treatment. Basal cell or squamous cell skin cancer or cervical carcinoma in situ and thyroid papillary carcinoma。
  • Patients who allergy to any component of the drugs in this protocol; patients with history of immunodeficiency, including HIV positive, HCV, active hepatitis B, or other acquired or congenital immunodeficiency diseases, or history of organ transplantation
  • History of any cardiac disease, including: (1) arrhythmia requiring medication or clinically significant; (2) myocardial infarction; (3) heart failure; (4) any other cardiac disease judged by the investigator to be unsuitable for participation in this trial, etc
  • According to the investigator's judgment, there are severe accompanying diseases that endanger the patient's safety or affect the completion of the study (including but not limited to uncontrolled severe hypertension, severe diabetes, active infection, etc.)
  • Pregnant or lactation female patients; females of childbearing age with a positive baseline pregnancy test or unwilling to take effective contraceptive measures during the entire trial period;
  • Urgent need for local treatment of brain metastasis
  • Immunohistochemistry HER2 positive (IHC 3 or IHC 2 ISH amplification)

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Sex
  • HER2-negative breast cancer brain metastases

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Some studies have shown that approximately 15% of patients with advanced hormone receptor (HR) positive breast cancer and 1/3 of triple negative breast cancer will develop brain metastasis. At present, there is no unified drug treatment standard for HER2-negative breast cancer brain metastasis (BCBM). The evidence of single traditional chemotherapy drug as the main treatment of brain metastasis is not sufficient. Some exploratory studies on HER2-negative BCBM have shown that the central nervous system objective response rate (CNS-ORR) of anti-angiogenic drugs combined with chemotherapy is around 55%-80%。 Adebrelimab (a humanized PD-L1 monoclonal antibody) specifically blocks the binding of PD-1 and PD-L1, terminates the immunosuppressive signal produced by T cells, and makes T cells re-recognize tumor cells and kill them, thereby inhibiting tumor growth. In China, Adebelizumab has been approved for using in combination with chemotherapy as a first-line treatment for extensive stage small cell lung cancer. Apatinib (a small molecule VEGFR tyrosine kinase inhibitor) mainly plays an anti-angiogenic effect in the treatment of malignant tumors by inhibiting VEGFR. Apatinib has been approved monotherapy for advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma that has progressed or relapsed after at least two systematic chemotherapies, advanced liver cancer that has failed or is intolerable after at least first-line systematic treatment, and first-line treatment in patients with unresectable or metastatic hepatocellular carcinoma combined with camrelizumab.

Read full original descriptionShow less

Due to the lack of effective drug therapy for HER2-negative BCBM, a variety of treatment combinations are still being explored. We hypothesized that adebrelimab plus apatinib and etoposide is an explorable and effective treatment for HER2- negative BCBM.

The group in the trial

  • Adebrelimab+Apatinib+EtoposideTreatment being tested

    Adebrelimab: 1200mg, ivgtt,administered on the first day of each cycle, with a cycle of 21 days. Apatinib: 250 mg, oral, once daily, continuous use, with a cycle of 21 days. Etoposide: 50mg/day, oral, administered on days 1-14 of each cycle, with a cycle of 21 days.

    Treatment: Adebrelimab, Apatinib, and Etoposide

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 3 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis: A Phase II Study
Plain-language title
Adebrelimab, apatinib and etoposide for HER2-negative breast cancer that spread to the brainGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT06418594, who can take part
Record updated
10 December 2024